Safety Reading Notes

Read safety context beside the research guide.

The CBDV-A source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 33895189

PubMed For Dummies Article

CBDV-A Evidence Review: the long-form source walk-through

Quick read
  • CBDV-A currently has 44 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33895189
  • The evidence classes most visible in the row language are insufficient (19), mechanistic or pharmacological (17), preclinical (6), and preliminary human (2). PMID 32335286
  • The study-design language most visible in the row language is Narrative or expert review (11), Animal study (11), Cellular or in vitro study (8), and other mapped categories (6). PMID 32825313
  • The repeated topics are Seizure and neurodevelopmental outcomes (21), receptor, target, or pharmacology mechanisms (12), receptor, target, metabolic, or pharmacology mechanisms (4), Skin and inflammatory dermatology (2), and other mapped categories (5), which tells the reader where to start opening PubMed and DOI links. PMID 39968488

Start with the research question

CBDV-A is built from 44 source-backed evidence row(s) and 40 research source(s). The current evidence classes read as insufficient (19), mechanistic or pharmacological (17), preclinical (6), and preliminary human (2), and the study-design language most often reads as Narrative or expert review (11), Animal study (11), Cellular or in vitro study (8), and other mapped categories (6). PMID 33895189

The row-level question is not simply whether CBDV-A is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Seizure and neurodevelopmental outcomes (21), receptor, target, or pharmacology mechanisms (12), receptor, target, metabolic, or pharmacology mechanisms (4), Skin and inflammatory dermatology (2), and other mapped categories (5). PMID 36257598

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 42339654

Preclinical evidence 6 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 33613289

Mechanistic evidence 16 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 29842819

Limits and uncertainty 20 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 35364618

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 25475762

Where this page has the most source density

The largest bucket surfaced for this page is Seizure and neurodevelopmental outcomes. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, target, or pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 33895189

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 36257598

Bucket chapters: what the literature is circling

Seizure and neurodevelopmental outcomes

21 research sources 21 rows (40-124) Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (3), preclinical (5), preliminary human (2)

CBDV-A appears in rows studying Seizure and neurodevelopmental outcomes. It currently draws from 21 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 33895189

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 33895189

  • Evidence row 40

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related o... PMID 33895189

  • Evidence row 124

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopm... PMID 41159452

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (201-287) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

CBDV-A appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36257598

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36257598

  • Evidence row 201

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598

  • Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

Receptor, target, metabolic, and pharmacology mechanisms

3 research sources 3 rows (765-782) Mechanistic research summary: mechanistic or pharmacological (3)

CBDV-A appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21175579

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21175579

  • Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 21175579

  • Evidence row 782

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 30074247

receptor, target, or pharmacology mechanisms

3 research sources 3 rows (279-281) Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (1)

CBDV-A appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 34980287

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34980287

  • Evidence row 279

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharma... PMID 34980287

  • Evidence row 281

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

receptor, target, or pharmacology mechanisms

2 research sources 2 rows (283-284) Mapped evidence with interpretation limits: insufficient (2)

CBDV-A appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39808700

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39808700

  • Evidence row 283

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700

  • Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target,... PMID 35306000

Appetite and metabolic outcomes

1 research source 81 Mechanistic research summary: mechanistic or pharmacological (1)

CBDV-A appears in rows studying Appetite and metabolic outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39968488

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39968488

  • Evidence row 81

    THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 39968488

Receptor, target, metabolic, and pharmacology mechanisms

1 research source 580 Mechanistic research summary: mechanistic or pharmacological (1)

CBDV-A appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 40706771

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40706771

  • Evidence row 580

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome... PMID 40706771

receptor, target, or pharmacology mechanisms

1 research source 282 Mapped evidence with interpretation limits: insufficient (1)

CBDV-A appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 32824356

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 32824356

  • Evidence row 282

    CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target... PMID 32824356

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (16 row(s)), and safety/tolerability context (1 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33895189

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 36257598

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 24282673
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 29588939
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 28799516

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33895189

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 36257598

Source-reading checklist for CBDV-A

  1. Open the linked PubMed or DOI record. PMID 28845714
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 30633929
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 29214639
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 22970845
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 31447649

Source Notes

CBDV-A source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 40

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 33895189

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.
  2. Evidence row 41

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 32335286

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol.
  3. Evidence row 42

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 32825313

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.
  4. Evidence row 81

    THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 39968488

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.
  5. Evidence row 84

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 42339654

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.
  6. Evidence row 85

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 33613289

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
  7. Evidence row 109

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29842819

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Investigational cannabinoids in seizure disorders, what have we learned thus far?
  8. Evidence row 110

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 35364618

    Evidence class: preclinical; Study design: Human clinical study. Source: Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.
  9. Evidence row 111

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 25475762

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids and epilepsy.
  10. Evidence row 112

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (outcome measure: seizure-related or neurodevelopmental outcomes). PMID 24282673

    Evidence class: preclinical. Source: Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.
  11. Evidence row 113

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29588939

    Evidence class: preclinical. Source: Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.
  12. Evidence row 114

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 28799516

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Antiepileptic Drugs in Clinical Development: Differentiate or Die?
  13. Evidence row 115

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 28845714

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The potential role of cannabinoids in epilepsy treatment.
  14. Evidence row 116

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 30633929

    Evidence class: preclinical; Study design: Animal study. Source: Preclinical safety and efficacy of cannabidivarin for early life seizures.
  15. Evidence row 117

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29214639

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for epilepsy: What do we know and where do we go?
  16. Evidence row 118

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 22970845

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidivarin is anticonvulsant in mouse and rat.
  17. Evidence row 119

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 31447649

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.
  18. Evidence row 120

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 34210360

    Evidence class: preliminary human; Study design: Human clinical study. Source: Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin.
  19. Evidence row 121

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 36583706

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.
  20. Evidence row 122

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 31748505

    Evidence class: preliminary human; Study design: Human clinical study. Source: Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.
  21. Evidence row 123

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Systematic review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 39541799

    Evidence class: insufficient; Study design: Systematic review. Source: Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.
  22. Evidence row 124

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 41159452

    Evidence class: preclinical; Study design: Animal study. Source: The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.
  23. Evidence row 201

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598

    Evidence class: insufficient. Source: Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.
  24. Evidence row 277

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 37083031

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Antiviral activities of hemp cannabinoids.
  25. Evidence row 278

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 38162115

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.
  26. Evidence row 279

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34980287

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.
  27. Evidence row 280

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142

    Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
  28. Evidence row 281

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
  29. Evidence row 282

    CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 32824356

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus.
  30. Evidence row 283

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700

    Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
  31. Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  32. Evidence row 285

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 37708768

    Evidence class: insufficient. Source: Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid.
  33. Evidence row 286

    THCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39013926

    Evidence class: insufficient. Source: Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.
  34. Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

    Evidence class: insufficient. Source: Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.
  35. Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  36. Evidence row 580

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40706771

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.
  37. Evidence row 619

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  38. Evidence row 668

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40706771

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.
  39. Evidence row 707

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  40. Evidence row 752

    THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37305187

    Evidence class: mechanistic or pharmacological; Study design: Case report or case series. Source: Hair Regrowth with Novel Hemp Extract: A Case Series.
  41. Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  42. Evidence row 781

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 34500785

    Evidence class: mechanistic or pharmacological. Source: An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.
  43. Evidence row 782

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30074247

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
  44. Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.